

Philippe Saiag is board-certified both in dermatology and oncology. He obtained his MD in 1985, and his PhD in 1992. He is professor of Dermatology at the university of Versailles-Paris-Saclay, France, since 1993, and leads the department of General and Oncologic Dermatology at Ambroise Paré Hospital In Boulogne-Billancourt, at the border of inner Paris city.

His main topic is on the prognosis and treatment of skin cancers. He has published to date 291 studies referenced in pubmed. He published many contributions on melanoma, the most recent being the validation of a gene signature of therapeutic interest, an important prospective study on the role of Vitamin D published in the JNCI, the demonstration of the clinical value of dosing BRAFinhibitor serum levels to improve efficacy of Vemurafenib, on the role of hypofractionated radiotherapy in patients not responding to immune checkpoint blockers, etc. He is also deeply involved in the development of French and European guidelines for melanoma and Dermatofibroma protuberans, and leads the Merkel carcinoma branch of the French national network on rare skin cancers (CARADERM).